GlobeNewswire Inc.··Olema OncologyOlema's KAT6 Inhibitor Shows Promise With No Dose Limits in Phase 1 Trial
Olema Oncology's KAT6 inhibitor OP-3136 shows no dose-limiting toxicities and tumor shrinkage in two-thirds of patients in Phase 1 trial, advancing monotherapy and combination development strategies.
OLMAbreast cancerPhase 1 clinical trial